Double Blind Controlled Clinical Investigation into the Efficacy and Tolerability of subcutaneously administered Treprostinil Sodium in Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension

MRN-Medical Research Network GmbH0 个研究点目标入组 100 人开始时间: 2010年1月28日最近更新: 2012年3月19日

试验速览

暂无简介。

•1.Written informed consent has been obtained
•2.Patient should be notified of how their information will be handled and possibly shared with regulatory agencies when needed.
•3.Males or females, ages >18 years, of any racial origin with severe CTEPH with at least 3 months anticoagulation.
•4.Women of child bearing potential are surgically sterile or postmenopausal (amenorrhea for at least 12 months) or on acceptable form of birth control. A double barrier method of birth control, such as a condom and spermicide is mandatory.
•5.An un-encouraged six minute walk (6MWT) test of between 150 and 400 meters
•6.Cardiac catheterization within the past 6 months consistent with PH, specifically PAPm >25 mmHg (at rest), PCWP (or left ventricular end diastolic pressure) <15 mmHg, and PVR >3 mmHg/L/min
•7.Within the past 12 months patients must have had a chest radiograph or an alternative diagnostic imaging consistent with the diagnosis of PH.
•8.Be willing and able to follow all study procedures
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1.Have any other form of pulmonary hypertension, pulmonary venous hypertension, peripheral vascular occlusive disease (PVOD) or PCH, or severe chronic obstructive pulmonary disease (COPD).
•2.Be considering pregnancy, be pregnant and/or lactating
•3.Have any acute concomitant disease other than those accepted as part of the inclusion criteria
•4.Have received any prostanoid, within the 30 days before screening or be scheduled to receive any during the course of the study
•5.Have an increased risk for hemorrhage (INR >3)
•6.Have received any investigational medication within 30 days prior to the start of this study or be scheduled to receive another investigational drug during the course of this study
•7.Have a known intolerance to any drug, especially to treprostinil sodium or prostanoids
•8.Have a history or suspicion of inability to cooperate adequately
•9.Have a new type of chronic therapy (e.g., a different category of vasodilator, diuretic) for PAH added within the last month, excepting anticoagulants
•10.Have any preexisting disease known to cause pulmonary hypertension (e.g., obstructive lung disease, parasitic disease affecting the pulmonary system, sickle cell anemia, mitral valve stenosis, portal hypertension)
•11.Have any musculoskeletal disease or any other disease that would limit ambulation.
•12.Have any serious liver problems (Child-Pugh, class C), such as active gastrointestinal ulcer, intrabdominal hemorrhaging.

发起方

MRN-Medical Research Network GmbH